Search Results - "Hasson, Brooke R."

End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics by Goldsmith, Jason, Tomkovich, Sarah, Auniņš, John G, McGovern, Barbara H, Mahoney, Jennifer C, Hasson, Brooke R, McChalicher, Christopher W J, Ege, David S

“…Advances in microbiome therapeutics have been motivated by a deeper understanding of the role that the gastrointestinal microbiome plays in human health and…”
Get full text

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI) by Khanna, Sahil, Sims, Matthew, Louie, Thomas J, Fischer, Monika, LaPlante, Kerry, Allegretti, Jessica, Hasson, Brooke R, Fonte, Allyson T, McChalicher, Christopher, Ege, David S, Bryant, Jessica A, Straub, Timothy J, Ford, Christopher B, Henn, Matthew R, Wang, Elaine E L, von Moltke, Lisa, Wilcox, Mark H

“…Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly…”
Get full text

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool by McChalicher, Christopher W J, Lombardo, Mary-Jane, Khanna, Sahil, McKenzie, Gregory J, Halvorsen, Elizabeth M, Almomani, Sanabel, Schuster, Brian, Hasson, Brooke R, McGovern, Barbara H, Ege, David S, Auniņš, John G

“…Abstract Background Although fecal microbiota transplant has been used to prevent recurrent Clostridioides difficile infection (rCDI), documented pathogen…”
Get full text

Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection by Straub, Timothy J, Lombardo, Mary-Jane, Bryant, Jessica A, Diao, Liyang, Lodise, Thomas P, Freedberg, Daniel E, Wortman, Jennifer R, Litcofsky, Kevin D, Hasson, Brooke R, McGovern, Barbara H, Ford, Christopher B, Henn, Matthew R

“…Abstract Background The gastrointestinal microbiota is an important line of defense against colonization with antimicrobial resistant (AR) bacteria. In this…”
Get full text

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic by Berenson, Charles S, Lashner, Bret, Korman, Louis Y, Hohmann, Elizabeth, Deshpande, Abhishek, Louie, Thomas J, Sims, Matthew, Pardi, Darrell, Kraft, Colleen S, Wang, Elaine E L, Cohen, Stuart H, Feuerstadt, Paul, Oneto, Caterina, Misra, Bharat, Pullman, John, De, Ananya, Memisoglu, Asli, Lombardi, David A, Hasson, Brooke R, McGovern, Barbara H, von Moltke, Lisa, Lee, Christine H

“…Abstract Background Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with…”
Get full text

Racial/Ethnic Differences in Insulin Resistance and Beta Cell Function: Relationship to Racial Disparities in Type 2 Diabetes among African Americans versus Caucasians by Hasson, Brooke R., Apovian, Caroline, Istfan, Nawfal

“…Both biological and sociocultural factors have been implicated in the well-documented racial disparity in incidence and prevalence of type 2 diabetes (T2D)…”
Get full text

Preliminary Results of the Open-Label Phase of a 2-Part Phase 1b Study That Evaluates Safety, Tolerability, Pharmacokinetics, and Efficacy of Investigational Microbiome Therapeutic SER-155 in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT) by Ponce, Doris M., Kosuri, Satyajit, Khera, Nandita, DeFilipp, Zachariah, Lichter, David, Lombardo, Mary-Jane, Peled, Jonathan U., van den Brink, Marcel R.M., Chafee, Meghan, Wortman, Jennifer R, Straub, Timothy, Walsh, Emily, Ge, Augustus, Lyttle, David, Brady, Kelly, Puhl, Matthew D, Glick, Gabrielle, Hasson, Brooke R, Tejura, Bina, Ford, Christopher B, Henn, Matthew R, von Moltke, Lisa

“…In patients undergoing allo-HCT, low gastrointestinal (GI) microbial diversity is associated with adverse outcomes including bloodstream infections (BSIs) and…”
Get full text

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent IClostridioides difficile/I Infection by Khanna, Sahil, Sims, Matthew, Louie, Thomas J, Fischer, Monika, LaPlante, Kerry, Allegretti, Jessica, Hasson, Brooke R, Fonte, Allyson T, McChalicher, Christopher, Ege, David S, Bryant, Jessica A, Straub, Timothy J, Ford, Christopher B, Henn, Matthew R, Wang, Elaine E. L, von Moltke, Lisa, Wilcox, Mark H

“…Clostridioidesdifficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly…”
Get full text